Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Fibrogenesis & Tissue Repair
Published in: Fibrogenesis & Tissue Repair 1/2014

Open Access 01-12-2014 | Review

The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis

Authors: Juan S Danobeitia, Arjang Djamali, Luis A Fernandez

Published in: Fibrogenesis & Tissue Repair | Issue 1/2014

Login to get access

Abstract

The complement system is a major component of innate immunity and has been commonly identified as a central element in host defense, clearance of immune complexes, and tissue homeostasis. After ischemia-reperfusion injury (IRI), the complement system is activated by endogenous ligands that trigger proteolytic cleavage of complement components via the classical, lectin and/or alternative pathway. The result is the formation of terminal complement components C3a, C5a, and the membrane attack complex (C5b-9 or MAC), all of which play pivotal roles in the amplification of the inflammatory response, chemotaxis, neutrophil/monocyte recruitment and activation, and direct tubular cell injury. However, recent evidence suggests that complement activity transcends innate host defense and there is increasing data suggesting complement as a regulator in processes such as allo-immunity, stem cell differentiation, tissue repair, and progression to fibrosis. In this review, we discuss recent advances addressing the role of complement as a regulator of IRI and renal fibrosis after organ donation for transplantation. We will also briefly discuss currently approved therapies that target complement activity in kidney ischemia-reperfusion and transplantation.
Appendix
Available only for authorised users
Literature
1.
Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010, 11 (9): 785-797. 10.1038/ni.1923.PubMedCentralPubMedCrossRef
2.
Ricklin D, Lambris JD: Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013, 190 (8): 3831-3838. 10.4049/jimmunol.1203487.PubMedCentralPubMedCrossRef
3.
Zipfel PF, Skerka C: Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009, 9 (10): 729-740.PubMed
4.
Blom AM, Villoutreix BO, Dahlbäck B: Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?. Mol Immunol. 2004, 40 (18): 1333-1346. 10.1016/j.molimm.2003.12.002.PubMedCrossRef
5.
Józsi M, Zipfel PF: Factor H family proteins and human diseases. Trends Immunol. 2008, 29 (8): 380-387. 10.1016/j.it.2008.04.008.PubMedCrossRef
6.
Davis AE: Biological effects of C1 inhibitor. Drug News Perspect. 2004, 17 (7): 439-446. 10.1358/dnp.2004.17.7.863703.PubMedCrossRef
7.
Eltzschig HK, Eckle T: Ischemia and reperfusion–from mechanism to translation. Nat Med. 2011, 17 (11): 1391-1401. 10.1038/nm.2507.PubMedCrossRef
8.
9.
Friedewald JJ, Rabb H: Inflammatory cells in ischemic acute renal failure. Kidney Int. 2004, 66 (2): 486-491. 10.1111/j.1523-1755.2004.761_3.x.PubMedCrossRef
10.
Bonventre JV, Zuk A: Ischemic acute renal failure: an inflammatory disease?. Kidney Int. 2004, 66 (2): 480-485. 10.1111/j.1523-1755.2004.761_2.x.PubMedCrossRef
11.
Diepenhorst GM, van Gulik TM, Hack CE: Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg. 2009, 249 (6): 889-899. 10.1097/SLA.0b013e3181a38f45.PubMedCrossRef
12.
Guo RF, Ward PA: Role of C5a in inflammatory responses. Annu Rev Immunol. 2005, 23: 821-852. 10.1146/annurev.immunol.23.021704.115835.PubMedCrossRef
13.
McCaughan JA, O'Rourke DM, Courtney AE: The complement cascade in kidney disease: from sideline to center stage. Am J Kidney Dis. 2013, 62 (3): 604-614. 10.1053/j.ajkd.2012.12.033.PubMedCrossRef
14.
Gasque P: Complement: a unique innate immune sensor for danger signals. Mol Immunol. 2004, 41 (11): 1089-1098. 10.1016/j.molimm.2004.06.011.PubMedCrossRef
15.
Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000, 105 (10): 1363-1371. 10.1172/JCI8621.PubMedCentralPubMedCrossRef
16.
Weiser MR, Williams JP, Moore FD, Kobzik L, Ma M, Hechtman HB, Carroll MC: Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med. 1996, 183 (5): 2343-2348. 10.1084/jem.183.5.2343.PubMedCrossRef
17.
Park P, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ: Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol Renal Physiol. 2002, 282 (2): F352-F357.PubMedCrossRef
18.
Lin T, Zhou W, Farrar CA, Hargreaves RE, Sheerin NS, Sacks SH: Deficiency of C4 from donor or recipient mouse fails to prevent renal allograft rejection. Am J Pathol. 2006, 168 (4): 1241-1248. 10.2353/ajpath.2006.050360.PubMedCentralPubMedCrossRef
19.
Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM: Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003, 170 (3): 1517-1523. 10.4049/jimmunol.170.3.1517.PubMedCrossRef
20.
de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA: The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol. 2004, 165 (5): 1677-1688. 10.1016/S0002-9440(10)63424-4.PubMedCentralPubMedCrossRef
21.
Møller-Kristensen M, Wang W, Ruseva M, Thiel S, Nielsen S, Takahashi K, Shi L, Ezekowitz A, Jensenius JC, Gadjeva M: Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol. 2005, 61 (5): 426-434. 10.1111/j.1365-3083.2005.01591.x.PubMedCrossRef
22.
Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, Ali YM, Dudler T, Parent B, Lhotta K, Wallis R, Farrar CA, Sacks S, Lee H, Zhang M, Iwaki D, Takahashi M, Fujita T, Tedford CE, Stover CM: Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2011, 108 (18): 7523-7528. 10.1073/pnas.1101748108.PubMedCentralPubMedCrossRef
23.
van der Pol P, Schlagwein N, van Gijlswijk DJ, Berger SP, Roos A, Bajema IM, de Boer HC, de Fijter JW, Stahl GL, Daha MR, van Kooten C: Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant. 2012, 12 (4): 877-887. 10.1111/j.1600-6143.2011.03887.x.PubMedCrossRef
24.
Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M, Divella C, Battaglia M, Lucarelli G, Annunziata G, Palazzo S, Selvaggi FP, Staffieri F, Crovace A, Daha MR, Mannesse M, van Wetering S, Paolo Schena F, Grandaliano G: Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010, 176 (4): 1648-1659. 10.2353/ajpath.2010.090276.PubMedCentralPubMedCrossRef
25.
Berger SP, Roos A, Mallat MJ, Fujita T, de Fijter JW, Daha MR: Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant. 2005, 5 (6): 1361-1366. 10.1111/j.1600-6143.2005.00841.x.PubMedCrossRef
26.
Damman J, Kok JL, Snieder H, Leuvenink HG, van Goor H, Hillebrands JL, van Dijk MC, Hepkema BG, Reznichenko A, van den Born J, de Borst MH, Bakker SJ, Navis GJ, Ploeg RJ, Seelen MA: Lectin complement pathway gene profile of the donor and recipient does not influence graft outcome after kidney transplantation. Mol Immunol. 2012, 50 (1–2): 1-8.PubMedCrossRef
27.
Bay JT, Sørensen SS, Hansen JM, Madsen HO, Garred P: Low mannose-binding lectin serum levels are associated with reduced kidney graft survival. Kidney Int. 2013, 83 (2): 264-271. 10.1038/ki.2012.373.PubMedCrossRef
28.
Heijnen BH, Straatsburg IH, Padilla ND, Van Mierlo GJ, Hack CE, Van Gulik TM: Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol. 2006, 143 (1): 15-23. 10.1111/j.1365-2249.2005.02958.x.PubMedCentralPubMedCrossRef
29.
Straatsburg IH, Boermeester MA, Wolbink GJ, van Gulik TM, Gouma DJ, Frederiks WM, Hack CE: Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. J Hepatol. 2000, 32 (5): 783-791. 10.1016/S0168-8278(00)80247-0.PubMedCrossRef
30.
Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, Moore FD, Carroll MC, Hechtman HB: Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol (1985). 1999, 86 (3): 938-942.
31.
Hill JH, Ward PA: The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971, 133 (4): 885-900. 10.1084/jem.133.4.885.PubMedCentralPubMedCrossRef
32.
Jordan JE, Montalto MC, Stahl GL: Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation. 2001, 104 (12): 1413-1418. 10.1161/hc3601.095578.PubMedCrossRef
33.
Sacks SH: Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur J Immunol. 2010, 40 (3): 668-670. 10.1002/eji.201040355.PubMedCrossRef
34.
Zhou W: The new face of anaphylatoxins in immune regulation. Immunobiology. 2012, 217 (2): 225-234. 10.1016/j.imbio.2011.07.016.PubMedCrossRef
35.
van der Touw W, Cravedi P, Kwan WH, Paz-Artal E, Merad M, Heeger PS: Cutting edge: receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. J Immunol. 2013, 190 (12): 5921-5925. 10.4049/jimmunol.1300847.PubMedCentralPubMedCrossRef
36.
Cravedi P, Leventhal J, Lakhani P, Ward SC, Donovan MJ, Heeger PS: Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am J Transplant. 2013, 13 (10): 2530-2539. 10.1111/ajt.12405.PubMedCrossRef
37.
Peng Q, Li K, Smyth LA, Xing G, Wang N, Meader L, Lu B, Sacks SH, Zhou W: C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012, 23 (9): 1474-1485. 10.1681/ASN.2011111072.PubMedCentralPubMedCrossRef
38.
de Vries B, Köhl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P, Buurman WA: Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol. 2003, 170 (7): 3883-3889. 10.4049/jimmunol.170.7.3883.PubMedCrossRef
39.
Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM: A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 2003, 63 (1): 134-142. 10.1046/j.1523-1755.2003.00737.x.PubMedCrossRef
40.
Zheng X, Zhang X, Feng B, Sun H, Suzuki M, Ichim T, Kubo N, Wong A, Min LR, Budohn ME, Garcia B, Jevnikar AM, Min WP: Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol. 2008, 173 (4): 973-980. 10.2353/ajpath.2008.080103.PubMedCentralPubMedCrossRef
41.
Djamali A, Muth BL, Ellis TM, Mohamed M, Fernandez LA, Miller KM, Bellingham JM, Odorico JS, Mezrich JD, Pirsch JD, D'Alessandro TM, Vidyasagar V, Hofmann RM, Torrealba JR, Kaufman DB, Foley DP: Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Int. 2013, 83 (6): 1185-1192. 10.1038/ki.2013.44.PubMedCentralPubMedCrossRef
42.
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM: Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011, 11 (11): 2405-2413. 10.1111/j.1600-6143.2011.03757.x.PubMedCrossRef
43.
Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010, 21 (8): 1398-1406. 10.1681/ASN.2009101065.PubMedCentralPubMedCrossRef
44.
Lerut E, Naesens M, Kuypers DR, Vanrenterghem Y, Van Damme B: Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation. 2007, 83 (11): 1416-1422. 10.1097/01.tp.0000266676.10550.70.PubMedCrossRef
45.
Dean PG, Park WD, Cornell LD, Gloor JM, Stegall MD: Intragraft gene expression in positive crossmatch kidney allografts: ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant. 2012, 12 (6): 1551-1563. 10.1111/j.1600-6143.2011.03964.x.PubMedCrossRef
46.
Floerchinger B, Oberhuber R, Tullius SG: Effects of brain death on organ quality and transplant outcome. Transplant Rev (Orlando). 2012, 26 (2): 54-59. 10.1016/j.trre.2011.10.001.CrossRef
47.
Danobeitia JS, Sperger JM, Hanson MS, Park EE, Chlebeck PJ, Roenneburg DA, Sears ML, Connor JX, Schwarznau A, Fernandez LA: Early activation of the inflammatory response in the liver of brain-dead non-human primates. J Surg Res. 2012, 176 (2): 639-648. 10.1016/j.jss.2011.10.042.PubMedCrossRef
48.
van der Hoeven J, Molema G, Ter Horst G, Freund R, Wiersema J, van Schilfgaarde R, Leuvenink H, Ploeg R: Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. Kidney Int. 2003, 64 (5): 1874-1882. 10.1046/j.1523-1755.2003.00272.x.PubMedCrossRef
49.
Damman J, Schuurs TA, Ploeg RJ, Seelen MA: Complement and renal transplantation: from donor to recipient. Transplantation. 2008, 85 (7): 923-927. 10.1097/TP.0b013e3181683cf5.PubMedCrossRef
50.
Kusaka M, Pratschke J, Wilhelm MJ, Ziai F, Zandi-Nejad K, Mackenzie HS, Hancock WW, Tilney NL: Activation of inflammatory mediators in rat renal isografts by donor brain death. Transplantation. 2000, 69 (3): 405-410. 10.1097/00007890-200002150-00017.PubMedCrossRef
51.
Pratt JR, Abe K, Miyazaki M, Zhou W, Sacks SH: In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol. 2000, 157 (3): 825-831. 10.1016/S0002-9440(10)64596-8.PubMedCentralPubMedCrossRef
52.
Pratt JR, Basheer SA, Sacks SH: Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002, 8 (6): 582-587. 10.1038/nm0602-582.PubMedCrossRef
53.
Damman J, Nijboer WN, Schuurs TA, Leuvenink HG, Morariu AM, Tullius SG, van Goor H, Ploeg RJ, Seelen MA: Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant. 2011, 26 (7): 2345-2354. 10.1093/ndt/gfq717.PubMedCrossRef
54.
Atkinson C, Varela JC, Tomlinson S: Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res. 2009, 105 (11): 1094-1101. 10.1161/CIRCRESAHA.109.194977.PubMedCentralPubMedCrossRef
55.
Damman J, Hoeger S, Boneschansker L, Theruvath A, Waldherr R, Leuvenink HG, Ploeg RJ, Yard BA, Seelen MA: Targeting complement activation in brain-dead donors improves renal function after transplantation. Transpl Immunol. 2011, 24 (4): 233-237. 10.1016/j.trim.2011.03.001.PubMedCrossRef
56.
Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh SC, Kambham N, Lerut E, Salvatierra O, Butte AJ, Sarwal MM: Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol. 2009, 20 (8): 1839-1851. 10.1681/ASN.2008111145.PubMedCentralPubMedCrossRef
57.
Damman J, Seelen MA, Moers C, Daha MR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ: Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011, 92 (2): 163-169. 10.1097/TP.0b013e318222c9a0.PubMedCrossRef
58.
van Werkhoven MB, Damman J, van Dijk MC, Daha MR, de Jong IJ, Leliveld A, Krikke C, Leuvenink HG, van Goor H, van Son WJ, Olinga P, Hillebrands JL, Seelen MA: Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant. 2013, 13 (4): 875-882. 10.1111/ajt.12130.PubMedCrossRef
59.
Błogowski W, Dołęgowska B, Sałata D, Budkowska M, Domański L, Starzyńska T: Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation. Clin J Am Soc Nephrol. 2012, 7 (11): 1843-1851. 10.2215/CJN.02200312.PubMedCentralPubMedCrossRef
60.
de Vries DK, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, Reinders ME, Schaapherder AF, Kooten C: Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013, 95 (6): 816-820. 10.1097/TP.0b013e31827e31c9.PubMedCrossRef
61.
Mastellos DC, Deangelis RA, Lambris JD: Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Semin Immunol. 2013, 25 (1): 29-38. 10.1016/j.smim.2013.04.002.PubMedCentralPubMedCrossRef
62.
Vasel M, Rutz R, Bersch C, Feick P, Singer MV, Kirschfink M, Nakchbandi IA: Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C. Clin Immunol. 2014, 150 (2): 149-156. 10.1016/j.clim.2013.11.014.PubMedCrossRef
63.
Khan MA, Nicolls MR: Complement-mediated microvascular injury leads to chronic rejection. Adv Exp Med Biol. 2013, 735: 233-246. 10.1007/978-1-4614-4118-2_16.PubMedCentralPubMedCrossRef
64.
Khan MA, Maasch C, Vater A, Klussmann S, Morser J, Leung LL, Atkinson C, Tomlinson S, Heeger PS, Nicolls MR: Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A. 2013, 110 (15): 6061-6066. 10.1073/pnas.1217991110.PubMedCentralPubMedCrossRef
65.
DeAngelis RA, Markiewski MM, Kourtzelis I, Rafail S, Syriga M, Sandor A, Maurya MR, Gupta S, Subramaniam S, Lambris JD: A complement-IL-4 regulatory circuit controls liver regeneration. J Immunol. 2012, 188 (2): 641-648. 10.4049/jimmunol.1101925.PubMedCentralPubMedCrossRef
66.
Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD: The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 2003, 198 (6): 913-923. 10.1084/jem.20030374.PubMedCentralPubMedCrossRef
67.
He S, Atkinson C, Qiao F, Cianflone K, Chen X, Tomlinson S: A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009, 119 (8): 2304-2316.PubMedCentralPubMed
68.
Su Z, Wang X, Gao X, Liu Y, Pan C, Hu H, Beyer RP, Shi M, Zhou J, Zhang J, Serra AL, Wüthrich RP, Mei C: Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. J Intern Med. 2014, In press
69.
Hepburn NJ, Ruseva MM, Harris CL, Morgan BP: Complement, roles in renal disease and modulation for therapy. Clin Nephrol. 2008, 70 (5): 357-376.PubMedCrossRef
70.
Mele C, Remuzzi G, Noris M: Hemolytic uremic syndrome. Semin Immunopathol. 2014, In press
71.
Sacks SH, Zhou W: The role of complement in the early immune response to transplantation. Nat Rev Immunol. 2012, 12 (6): 431-442. 10.1038/nri3225.PubMedCrossRef
72.
73.
Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK: Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant. 2008, 23 (3): 842-852.PubMedCrossRef
74.
Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, Molitoris BA: Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol. 2003, 285 (2): F191-F198.PubMedCrossRef
75.
Basile DP: The endothelial cell in ischemic acute kidney injury: implications for acute and chronic function. Kidney Int. 2007, 72 (2): 151-156. 10.1038/sj.ki.5002312.PubMedCrossRef
76.
Koo DD, Welsh KI, West NE, Channon KM, Penington AJ, Roake JA, Morris PJ, Fuggle SV: Endothelial cell protection against ischemia/reperfusion injury by lecithinized superoxide dismutase. Kidney Int. 2001, 60 (2): 786-796. 10.1046/j.1523-1755.2001.060002786.x.PubMedCrossRef
77.
Tipping PG, Huang XR, Berndt MC, Holdsworth SR: A role for P selectin in complement-independent neutrophil-mediated glomerular injury. Kidney Int. 1994, 46 (1): 79-88. 10.1038/ki.1994.246.PubMedCrossRef
78.
Boor P, Konieczny A, Villa L, Schult AL, Bücher E, Rong S, Kunter U, van Roeyen CR, Polakowski T, Hawlisch H, Hillebrandt S, Lammert F, Eitner F, Floege J, Ostendorf T: Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol. 2007, 18 (5): 1508-1515. 10.1681/ASN.2006121343.PubMedCrossRef
79.
Bao L, Wang Y, Haas M, Quigg RJ: Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury. Kidney Int. 2011, 80 (5): 524-534. 10.1038/ki.2011.158.PubMedCrossRef
80.
Guerrot D, Dussaule J-C, Kavvadas P, Boffa J-J, Chadjichristos CE, Chatziantoniou C: Progression of renal fibrosis: the underestimated role of endothelial alterations. Fibrogenesis Tissue Repair. 2012, 5 (Suppl 1): S15-10.1186/1755-1536-5-S1-S15.PubMedCentralPubMedCrossRef
81.
Basile DP, Friedrich JL, Spahic J, Knipe N, Mang H, Leonard EC, Changizi-Ashtiyani S, Bacallao RL, Molitoris BA, Sutton TA: Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol. 2011, 300 (3): F721-F733. 10.1152/ajprenal.00546.2010.PubMedCentralPubMedCrossRef
82.
Curci C, Castellano G, Stasi A, Divella C, Loverre A, Gigante M, Simone S, Cariello M, Montinaro V, Lucarelli G, Ditonno P, Battaglia M, Crovace A, Staffieri F, Oortwijn B, van Amersfoort E, Gesualdo L, Grandaliano G: Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant. 2014, 29 (4): 799-808. 10.1093/ndt/gft516.PubMedCrossRef
83.
Wan JX, Fukuda N, Endo M, Tahira Y, Yao EH, Matsuda H, Ueno T, Matsumoto K: Complement 3 is involved in changing the phenotype of human glomerular mesangial cells. J Cell Physiol. 2007, 213 (2): 495-501. 10.1002/jcp.21129.PubMedCrossRef
84.
Rangan GK, Pippin JW, Couser WG: C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int. 2004, 66 (5): 1838-1848. 10.1111/j.1523-1755.2004.00957.x.PubMedCrossRef
85.
86.
Mannon RB: Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders?. Curr Opin Organ Transplant. 2012, 17 (1): 20-25. 10.1097/MOT.0b013e32834ee5b6.PubMedCentralPubMedCrossRef
87.
Li L, Huang L, Sung SS, Vergis AL, Rosin DL, Rose CE, Lobo PI, Okusa MD: The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Inter. 2008, 74 (12): 1526-1537. 10.1038/ki.2008.500.CrossRef
88.
Phieler J, Chung K-J, Chatzigeorgiou A, Ameln AK-v, Garcia-Martin R, Sprott D, Moisidou M, Tzanavari T, Ludwig B, Baraban E, Ehrhart-Bornstein M, Bornstein SR, Mziaut H, Solimena M, Karalis KP, Economopoulou M, Lambris JD, Chavakis T: The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol. 2013, 191 (8): 4367-4374. 10.4049/jimmunol.1300038.PubMedCrossRef
89.
Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007, 87 (1): 245-313. 10.1152/physrev.00044.2005.PubMedCrossRef
90.
Gill PS, Wilcox CS: NADPH oxidases in the kidney. Antioxid Redox Signal. 2006, 8 (9–10): 1597-1607.PubMedCrossRef
91.
Gardinali M, Padalino P, Vesconi S, Calcagno A, Ciappellano S, Conciato L, Chiara O, Agostoni A, Nespoli A: Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease. Arch Surg. 1992, 127 (10): 1219-1224. 10.1001/archsurg.1992.01420100077014.PubMedCrossRef
92.
Igonin AA, Protsenko DN, Galstyan GM, Vlasenko AV, Khachatryan NN, Nekhaev IV, Shlyapnikov SA, Lazareva NB, Herscu P: C1-esterase inhibitor infusion increases survival rates for patients with sepsis*. Crit Care Med. 2012, 40 (3): 770-777. 10.1097/CCM.0b013e318236edb8.PubMedCrossRef
93.
Djamali A, Reese S, Hafez O, Vidyasagar A, Jacobson L, Swain W, Kolehmainen C, Huang L, Wilson NA, Torrealba JR: Nox2 is a mediator of chronic CsA nephrotoxicity. Am J Transplant. 2012, 12 (8): 1997-2007. 10.1111/j.1600-6143.2012.04081.x.PubMedCentralPubMedCrossRef
94.
95.
Davis AE, Lu F, Mejia P: C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost. 2010, 104 (5): 886-893. 10.1160/TH10-01-0073.PubMedCrossRef
96.
Frank MM: Recombinant and plasma-purified human c1 inhibitor for the treatment of hereditary angioedema. World Allergy Organ J. 2010, 3 (9 Suppl): S29-S33.PubMedCentralPubMed
97.
Lu F, Chauhan AK, Fernandes SM, Walsh MT, Wagner DD, Davis AE: The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2008, 295 (5): G1042-G1049. 10.1152/ajpgi.90460.2008.PubMedCrossRef
98.
Lu F, Fernandes SM, Davis AE: The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc Pathol. 2013, 22 (1): 75-80. 10.1016/j.carpath.2012.05.003.PubMedCentralPubMedCrossRef
99.
Saidi RF, Rajeshkumar B, Shariftabrizi A, Dresser K, Walter O: Human C1 inhibitor attenuates liver ischemia-reperfusion injury and promotes liver regeneration. J Surg Res. 2014, 187 (2): 660-666. 10.1016/j.jss.2013.09.009.PubMedCrossRef
100.
Gesuete R, Storini C, Fantin A, Stravalaci M, Zanier ER, Orsini F, Vietsch H, Mannesse ML, Ziere B, Gobbi M, De Simoni MG: Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol. 2009, 66 (3): 332-342. 10.1002/ana.21740.PubMedCrossRef
101.
Tillou X, Poirier N, Le Bas-Bernardet S, Hervouet J, Minault D, Renaudin K, Vistoli F, Karam G, Daha M, Soulillou JP, Blancho G: Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int. 2010, 78 (2): 152-159. 10.1038/ki.2010.75.PubMedCrossRef
102.
Sommer W, Tudorache I, Kühn C, Avsar M, Salman J, Ius F, Gras C, Weber P, Welte T, Gottlieb J, Haverich A, Warnecke G: C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation. 2014, 97 (11): 1185-1191. 10.1097/TP.0000000000000034.PubMedCrossRef
103.
Barnett AN, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N: The use of eculizumab in renal transplantation. Clin Transplant. 2013, 27 (3): E216-E229. 10.1111/ctr.12102.PubMedCrossRef
104.
De Vries B, Matthijsen RA, Wolfs TG, Van Bijnen AA, Heeringa P, Buurman WA: Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation. 2003, 75 (3): 375-382. 10.1097/01.TP.0000044455.05584.2A.PubMedCrossRef
Metadata
Title
The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis
Authors
Juan S Danobeitia
Arjang Djamali
Luis A Fernandez
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Fibrogenesis & Tissue Repair / Issue 1/2014
Electronic ISSN: 1755-1536
DOI
https://doi.org/10.1186/1755-1536-7-16

Other articles of this Issue 1/2014

Fibrogenesis & Tissue Repair 1/2014 Go to the issue

Research

Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice

Research

Secreted frizzled related proteins inhibit fibrosis in vitro but appear redundant in vivo

Meeting Report

Highlights of Keystone symposium ‘Fibrosis: from bench to bedside’

Review

Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review

Meeting Report

The 23rd Annual Meeting of the European Tissue Repair Society (ETRS) in Reims, France

Research

Deficient repair response of IPF fibroblasts in a co-culture model of epithelial injury and repair
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits